Welcome to this month's episode of the Let’s Talk Rare podcast brought to you by Partners4Acess. Georgie and Owen are joined by Chloe Sheppard and Akshay Kumar to discuss the new EU HTA regulation set to be implemented in 2025. They explore the implications for drug developers of ATMPs, the attractiveness of the EU market, and the importance of proactive preparation for the upcoming changes.
The topics covered include: key milestones of the EU HTA regulation; the importance of drug developers of ATMPs and oncology medicines to not adopt a wait and watch strategy; the risks of ignoring this change and the potential impact on clinical development plans, commercialization strategies, and patient access; the opportunities the EU market presents; and the need to start planning and adapting internal processes to successfully navigate the new regulatory landscape.
Chloe Sheppard Bio:
Chloe serves as a Senior Consultant at Partners4Access, working closely with clients to craft custom solutions for their pricing and market access obstacles. Her motivation lies in transforming the immense potential of advanced medicines into tangible therapeutic benefits for patients.
Akshay Kumar Bio:
Akshay, a Partner at Partners4Access, brings over 13 years of experience assisting pharmaceutical companies in devising market access and pricing strategies that align with their broader commercial and organizational contexts. His expertise spans not only product-level solutions but also process improvements and capability enhancement. In addition to market access, Akshay is well-versed in various other aspects of drug commercialization, including opportunity assessments, product positioning, forecasting, customer insights, and organizational design.
Episode Resources:
Chloe’s LinkedIn
Akshay’s LinkedIn
Partners 4 Access Website
The Role of Patient Experience Data in Drug Development with Pina Haberl and Sam Morrison
World EPA Conference 2024 Special
Rare Disease Day Special 2024: The Role of Genetic Diagnosis in Rare Conditions with Nick Meade
Celebrating 5 Years of P4A: Reflections on Rare Diseases, Cell and Gene Therapies, and Legislation in Europe
Revolutionizing Patient Outcomes: The Power of Digital Health Solutions with RJ Kedziora
The Future of Patient Engagement and the Role of Technology in Healthcare with Iola Forster
Alejandro Dorenbaum, CMO of Reneo Pharmaceuticals Discusses Clinical-Stage Therapies
Interview with Xortx Therapeutics CEO, Dr Allen Davidoff discussing their journey from early development to potential launch
World EPA Congress 2023 Special
Rare Disease Day Special 2023
Trends to look out for in 2023
World Orphan Drug Congress Europe 2022 Special
Winds of change for German Healthcare Market!
Part 2 -Patient Empowerment: Is it a no-brainer?
Part 1 Patient Empowerment; Why involving patients from early drug development through to launch is a no-brainer!
What makes P4A an award winning consultancy?
Special Episode with EUCOPE-Part 2 with Alexander Natz
Special series with Eucope: Part 1 featuring Victor Maertens
China market access: obstacle or opportunity for orphan drug, cell and gene therapy manufacturers?
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain